due

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHAkero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

January 24, 2025 16:05 ET  | Source: Akero Therapeutics Inc. Investor webcast on Monday, January 27, 2025, at 8:00 a.m.…

2 months ago
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHAkero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

January 24, 2025 16:05 ET  | Source: Akero Therapeutics Inc. Investor webcast on Monday, January 27, 2025, at 8:00 a.m.…

2 months ago
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHAkero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

January 24, 2025 16:05 ET  | Source: Akero Therapeutics Inc. Investor webcast on Monday, January 27, 2025, at 8:00 a.m.…

2 months ago
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-NovartisMediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

November 11, 2024 18:00 ET | Source: MediciNova, Inc. LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc.,…

4 months ago